Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years

Glioblastoma in Elderly Patients: Current Management and Future Perspectives

(2019) Giuseppe Minniti et al.   Cancers

Treatment outcomes of hypofractionated radiotherapy combined with temozolomide followed by bevacizumab salvage therapy in glioblastoma patients aged > 75 years

(2018) Ken-ichiro Matsuda et al.   International Journal of Clinical Oncology

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy

(2017) Georgia Harris et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline

(2017) Erik P. Sulman et al.   JOURNAL OF CLINICAL ONCOLOGY

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

(2017) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Brain Tumor Registry of Japan (2005-2008)

(2017)   NEUROLOGIA MEDICO-CHIRURGICA

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report

(2017) J. Biau et al.   Radiation Oncology

Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma

(2016) Megumi Uto et al.   International Journal of Clinical Oncology

Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival

(2016) Ranjith Babu et al.   JOURNAL OF NEUROSURGERY

Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma

(2016) Nicole R. Parker et al.   Scientific Reports

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

(2015) Wilson Roa et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)

(2015) Giuseppe Lombardi et al.   JOURNAL OF NEURO-ONCOLOGY

Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas

(2014) Hideyuki Arita et al.   Brain Tumor Pathology

Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features

(2014) Yu Jin Lim et al.   International Journal of Clinical Oncology

Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

(2014) Toshihiko Iuchi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study

(2013) Takeo Uzuka et al.   JOURNAL OF NEURO-ONCOLOGY

Toxicity and Outcome of Radiotherapy with Concomitant and Adjuvant Temozolomide in Elderly Patients with Glioblastoma: A Retrospective Study

(2013) Kuniaki SAITO et al.   NEUROLOGIA MEDICO-CHIRURGICA

Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future?

(2012) M Hingorani et al.   BRITISH JOURNAL OF RADIOLOGY

Optimal management of elderly patients with glioblastoma

(2012) Normand Laperriere et al.   CANCER TREATMENT REVIEWS

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Phase II Study of Short-Course Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Elderly Patients With Glioblastoma

(2011) Giuseppe Minniti et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme

(2010) Mizuhiko Terasaki et al.   JOURNAL OF NEURO-ONCOLOGY

Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues

(2010) Dante Amelio et al.   RADIOTHERAPY AND ONCOLOGY

Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience

(2009) P. L. Nghiemphu et al.   NEUROLOGY

Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma

(2008) Giuseppe Minniti et al.   JOURNAL OF NEURO-ONCOLOGY